Calculated red marrow absorbed dose in patients receiving radioimmunotherapy (RAIT) has
not been highly predictive of the dose-limiting hematologic toxicity observed in many patient …

PURPOSE: To determine whether variations in the plasma Flt-3 ligand (FL) concentration
after radiotherapy (RT) may serve as a biomarker for radiation-induced bone marrow …

BACKGROUND During the recovery period after anticancer myelosuppressive therapy,
hematopoietic progenitor cells become mitotically active in order to replenish the bone …

Potential radiogenic damage to the hematopoietic bone marrow is the primary dose-limiting
toxicity for systemic radionuclide therapy in general and radioimmunotherapy in particular. A …

BACKGROUND The severity of myelotoxicity after radioimmunotherapy has been predicted
from body and blood radiation doses to marrow. However, marrow radiation can be …

Background Red bone marrow (RBM) toxicity is dose-limiting in (pretargeted)
radioimmunotherapy (RIT). Previous blood-based and two-dimensional (2D) image-based …

The radiation dose‐limiting toxicity from radioimmu‐notherapy has been myelotoxicity in the
absence of bone marrow reconstitution (transplantation). Myelotoxicity can be assessed …

Myelotoxiclty is the dose-limiting factor in radioimmunotherapy. Traditional methods most
commonly used to estimate the radiation adsorbed dose to the bone marrow of patients …

In essentially all cases of intravenously administered administered radiolabeled antibody,
hematologic toxicity has limited the amount of radioactivity that may be administered. In this …

BACKGROUND Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to
reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell …